Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug BioSpaceJideytro is GSK's first approved product for lung cancer.OncologyRead full story pharminent July 23, 2026 (Last updated: July 23, 2026) BioSpace Jideytro is GSK’s first approved product for lung cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Arrowhead’s Plozasiran Cuts Triglycerides Roughly 80% in Two Phase 3 TrialsNext: Lilly plans Q1 2027 filing for obesity triple retatrutide Related Stories Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide pharminent July 23, 2026 Regulatory Celcuity gains FDA approval for closely watched breast cancer drug pharminent July 15, 2026 Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026
